<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496509</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00050</org_study_id>
    <nct_id>NCT00496509</nct_id>
  </id_info>
  <brief_title>Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability&#xD;
      In Patients with Advanced Colorectal Cancer and Liver Metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.</measure>
    <time_frame>Up to 57 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of appropriate Pharmacokinetic parameters</measure>
    <time_frame>Predetermined timepoints after dose administration</time_frame>
    <description>The exposure to ZD6474 in patients with advanced colorectal cancer and liver metastases by assessment of: maximum plasma concentration after single and at steady state (C max and Css, max); time to reach C max and Css, max (tmax); minimum plasma concentration before and at steady state (Cmin and Css, min); area under plasma concentration-time curve from zero to 24 h and at steady state (AUC(0-24) and AUCss); total body clearance of drug from plasma after an oral dose (CL/F): accumulation ratio (Rac) and fraction of ZD6474 unbound (fu).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity</measure>
    <time_frame>Predetermined timepoints after dose administration</time_frame>
    <description>Determination of the population PK of ZD6474 and the assessment of the relationship between both free and total plasma PK and measures of pharmacological activity by assessment of individual predicted plasma concentrations, individual predicted CL/F, AUCss, Css, max, and AUC to the point up to the scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.</measure>
    <time_frame>Every 8 weeks during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474 (Zactima) 100mg</intervention_name>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)</intervention_name>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biomarker Draws</intervention_name>
    <arm_group_label>ZD6474 (vandetanib) 100mg</arm_group_label>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474 (Zactima) 300mg</intervention_name>
    <arm_group_label>ZD6474 (vandetanib) 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma (stage IV) with at least&#xD;
             1 measurable hepatic lesion of 20 mm or more on MRI and for whom no standard therapy&#xD;
             is available.&#xD;
&#xD;
          -  WHO Performance status 0 - 2.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastases or spinal cord compression, unless treated at least 4 weeks before&#xD;
             entry and stable without steroid treatment for 10 days or greater.&#xD;
&#xD;
          -  Last dose of prior chemotherapy must be discontinued at least 4 weeks before the start&#xD;
             of study treatment.&#xD;
&#xD;
          -  Last dose of radiotherapy received within 4 weeks before the start of study treatment&#xD;
             excluding palliative radiotherapy.&#xD;
&#xD;
          -  Prior treatment with VEGFR TKIs&#xD;
&#xD;
          -  Serum bilirubin . 1.5 x the upper limit of reference range.&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x ULRR or Creatinine clearance (as determined by the Cockcroft -&#xD;
             Gault method) less than or equal to 50 mL/min.&#xD;
&#xD;
          -  ALT or AST &gt;5 x ULRR&#xD;
&#xD;
          -  ALP &gt;5 x ULRR&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic disease or any concurrent conditions which&#xD;
             in the investigators opinion make it undesirable for the patient to participate in the&#xD;
             study or would jeopardize compliance with the protocol.&#xD;
&#xD;
          -  Any unresolved toxicity greater than CTCAE Grade 2 for previous anti-cancer therapy.&#xD;
&#xD;
          -  Significant cardiovascular event within 3 months before entry, or presence of cardiac&#xD;
             disease that in the opinion of the investigator increases the risk of ventricular&#xD;
             arrhythmia.&#xD;
&#xD;
          -  History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or&#xD;
             asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled by&#xD;
             medication is not excluded.&#xD;
&#xD;
          -  Congenital long QT syndrome or 1st degree relative with sudden unexplained death under&#xD;
             of 40 years of age.&#xD;
&#xD;
          -  Presence of Left Bundle Branch Block.&#xD;
&#xD;
          -  QTc with Bazett's correction unmeasurable or greater than or equal to 480 msec or&#xD;
             greater of screening ECG.&#xD;
&#xD;
          -  Potassium &lt;4.0 mmol/L despite supplementation, serum calcium (ionized or adjusted for&#xD;
             albumin), or magnesium out of normal range despite supplementation.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding.&#xD;
&#xD;
          -  Any concomitant medications that may cause QTc prolongation or induce or induce&#xD;
             Torsades de Pointes or induce CTP3A4 function.&#xD;
&#xD;
          -  Hypotension not controlled by medical therapy.&#xD;
&#xD;
          -  Participation in a clinical study of any investigational pharmaceutical agent within&#xD;
             30 days prior to commencing study treatment.&#xD;
&#xD;
          -  Major surgery within 4 weeks or incompletely healed surgical incision.&#xD;
&#xD;
          -  Previous or current malignancies of other histologies within the last 5 years, with&#xD;
             the exception of in situ carcinoma of the cervix and adequately treated basal cell or&#xD;
             Squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Any contraindications to MRI scans.&#xD;
&#xD;
          -  Involvement in the planning or conduct of the study.&#xD;
&#xD;
          -  Previous enrollment or randomization of treatment in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Buchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, Ryan AJ, Fischer R. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res. 2009 Sep 21;1:5. doi: 10.1186/2040-2384-1-5.</citation>
    <PMID>19946413</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ZD6474</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

